4. Antibody Therapy for Malignant Lymphoma
スポンサーリンク
概要
- 論文の詳細を見る
Rituximab, a genetically engineered, chimeric anti-CD20 monoclonal antibody, induces the apoptosis of B-lymphoma cells, in addition to the lyses by complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), as shown in Fig. 1 (1). A Japanese phase I study of rituximab in relapsed or refractory patients with B-cell non-Hodgkins lymphoma (B-NHL) showed an overall response rate (ORR) of 64% (7/11) with minimal toxicities. Elimination half-life (T1/2) of serum rituximab was 445±361 hours, and the serum rituximab was detectable at three months. In the subsequent phase II study, 90 relapsed or refractory patients with indolent B-NHL or mantle cell lymphoma (MCL) were treated with rituximab at 375 mg/m2×4 weekly infusions. ORRs in indolent B-NHL and MCL were 61% (37/61) and 46% (6/13), respectively. In this presentation, the results of clinical trials of antibody therapy of malignant lymphoma are summarized, focusing on the two recent Japanese multicenter trials of rituximab and a Japanese feasibility study of anti-CD20 radioimmunotherapy with yttrium-90-lableled ibritumomab tiuxetan (2).
論文 | ランダム
- 余効すべり人工データを用いたアジョイント法による摩擦パラメータ・初期値の推定
- Adper Easy Bond の短期臨床成績
- 近位尿細管へのgentamicin蓄積に対する選択的アデノシンA1受容体拮抗薬KW-3902の作用
- ふれる--「法」とのかかわりで (「触れる」ことの人間学的研究)
- 「法による道徳の強制」再考(2・完)刑罰の正当化における道徳原理の意義